Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Targeting di Agonisti del Recettore del Peptide-1 Simile al Glucagone per la Sclerosi Multipla (TAG-MS)

9 novembre 2026 aggiornato da: Johns Hopkins University

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis (TAG-MS): Uno Studio di Fase 2, Randomizzato, in Doppio Cieco, con Bracci Paralleli

The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Study Manager
  • Numero di telefono: 667-306-8153
  • Email: mvieira4@jh.edu

Luoghi di studio

    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66103
        • Reclutamento
        • University of Kansas Medical Center
        • Investigatore principale:
          • Sharon Lynch, MD
        • Contatto:
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Reclutamento
        • Johns Hopkins University
        • Investigatore principale:
          • Ellen Mowry, MD, MCR
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10029
        • Reclutamento
        • Mount Sinai School of Medicine
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
  • Aged 18-60 years
  • Body mass index ≥27.0 kg/m2

Exclusion Criteria:

  • No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class

  • No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis

  • No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2

  • No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse

  • No concerns about candidacy of individual on part of person's neurologist or study team clinicians

  • Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable contraception (contraception requirements as discussed below)***

    • currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) & meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of childbearing potential (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of <1%/year, or two methods of lesser effectiveness:

Contraceptive methods with a failure rate of < 1% per year includes the following:

  • Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
  • Complete abstinence from sexual encounters with a person who has testes

Those who do not wish to use one of the above methods of contraception must use two methods. Options include:

  • Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.

  • Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:

    • A condom with or without spermicide

    • A cap, diaphragm, or sponge with or without spermicide

      • Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore placebo: Placebo

Placebo (saline solution)

Comparatore attivo: NLY01 (Study Drug)

5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage.

NLY01 is a pegylated exenatide

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in normalized (for head size) brain parenchymal volume (nBPV)
Lasso di tempo: Baseline, week 48, and week 96

Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation

Baseline, week 48, and week 96

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in normalized gray matter volume (mL)
Lasso di tempo: Baseline, week 48, and week 96

Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks).

Baseline, week 48, and week 96
Change in thalamic volume (mL)
Lasso di tempo: Baseline, week 48, and week 96

Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in cortical thickness (mm)
Lasso di tempo: Baseline, week 48, and week 96

Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation.

Baseline, week 48, and week 96
Change in retinal nerve fiber layer thickness
Lasso di tempo: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Change in ganglion cell/inner plexiform thickness
Lasso di tempo: Baseline, week 48, and week 96

Measured in μm, from randomization to end of treatment (approximately 96 weeks),

Baseline, week 48, and week 96
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function.

Approximately every 24 weeks, up to 96 weeks
Disability progression as assessed by the Expanded Disability Status Scale-Plus
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is >5.5).

Approximately every 24 weeks, up to 96 weeks
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Patient-Determined Disease Steps score range 0-8; higher is worse progression

Approximately every 24 weeks, up to 96 weeks
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
Lasso di tempo: Approximately every 24 weeks, up to 96 weeks

Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10.

Approximately every 24 weeks, up to 96 weeks
Adverse events
Lasso di tempo: From randomization to week 96

Proportion of individuals in each arm experiencing adverse events

From randomization to week 96
Serious adverse events
Lasso di tempo: From randomization to week 96

Proportion of individuals in each arm experiencing serious adverse events

From randomization to week 96

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Ellen M Mowry, MD, MCR, Johns Hopkins University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 aprile 2026

Completamento primario (Stimato)

1 gennaio 2030

Completamento dello studio (Stimato)

1 gennaio 2030

Date di iscrizione allo studio

Primo inviato

11 marzo 2026

Primo inviato che soddisfa i criteri di controllo qualità

24 marzo 2026

Primo Inserito (Effettivo)

27 marzo 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IRB00454859

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.

Periodo di condivisione IPD

Data will be available 6 months after publication and remain accessible for 12-24 months.

Criteri di accesso alla condivisione IPD

Qualified researchers who have completed and signed approvals for data sharing.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .